{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:32:31Z","timestamp":1787761951522,"version":"build-2784847793"},"reference-count":87,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Although antiphospholipid syndrome (APS) is best known for conveying increased risk of thrombotic events and pregnancy morbidity, thrombocytopenia is also recognized as a common association. In this review, we will explore the relationship between thrombocytopenia and APS, highlighting our evolving understanding \u2013 and persistent knowledge gaps \u2013 through clinically oriented questions and answers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>A history of thrombocytopenia likely portends a more severe APS phenotype (including increased risk of thrombosis). Although the pathophysiology underlying thrombocytopenia in APS has yet to be definitively revealed, mechanisms that play a role (at least in subsets of patients) include: immune thrombocytopenic purpura\/ITP-like autoantibodies against platelet glycoproteins; antiphospholipid antibody (aPL)-mediated platelet activation and consumption; and potentially life threatening thrombotic microangiopathy. Although thrombocytopenia is often \u2018mild\u2019 in APS (and therefore, may not require specific therapy), there are causes of acute-onset thrombocytopenia that mandate emergent work-up and treatment. When APS-related thrombocytopenia does require therapy, the approach must be individualized (requiring an understanding of pathophysiology in the particular APS patient). For patients with ITP-like disease, rituximab is emerging as a popular approach to treatment; in contrast, there are hints that thrombopoietin mimetics may be associated with elevated thrombotic risk.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Thrombocytopenia is common in APS, and is likely associated with more severe disease. Improved understanding of thrombocytopenia in APS has the potential to improve risk stratification, reveal novel aspects of APS pathophysiology, and lead to treatments that are more individualized and holistic.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000595","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T18:21:01Z","timestamp":1552587661000},"page":"231-240","source":"Crossref","is-referenced-by-count":38,"title":["Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome"],"prefix":"10.1097","volume":"31","author":[{"given":"Andrew P.","family":"Vreede","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, University of Michigan"},{"name":"Rheumatology Section, Ann Arbor Veterans Administration Healthcare System"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula L.","family":"Bockenstedt","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Joseph","family":"McCune","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, University of Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Knight","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, University of Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230828","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1586\/17474086.2016.1140034","article-title":"The challenges of lupus anticoagulants","volume":"9","author":"Chighizola","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"R2-20230828","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R3-20230828","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/annrheumdis-2018-213846","article-title":"Management of antiphospholipid syndrome","volume":"78","author":"Uthman","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R4-20230828","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R5-20230828","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0049-0172(92)90021-5","article-title":"Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus","volume":"21","author":"Alarcon-Segovia","year":"1992","journal-title":"Semin Arthritis Rheum"},{"key":"R6-20230828","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/rheumatology\/26.5.324","article-title":"Syndrome of the black swan","volume":"26","author":"Harris","year":"1987","journal-title":"Br J Rheumatol"},{"key":"R7-20230828","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.autrev.2015.01.002","article-title":"The relevance of \u2018noncriteria\u2019 clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features","volume":"14","author":"Abreu","year":"2015","journal-title":"Autoimmun Rev"},{"key":"R8-20230828","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/0961203310395052","article-title":"Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Noncriteria APS Manifestations (II): thrombocytopenia and skin manifestations","volume":"20","author":"Cervera","year":"2011","journal-title":"Lupus"},{"key":"R9-20230828","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.imbio.2005.10.005","article-title":"The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome","volume":"210","author":"Krause","year":"2005","journal-title":"Immunobiology"},{"key":"R10-20230828","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0049-0172(99)80029-8","article-title":"Clinical study and follow-up of 100 patients with the antiphospholipid syndrome","volume":"29","author":"Munoz-Rodriguez","year":"1999","journal-title":"Semin Arthritis Rheum"},{"key":"R11-20230828","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1177\/0961203314531839","article-title":"Nonthromboembolic risk in systemic lupus erythematosus associated with antiphospholipid syndrome","volume":"23","author":"Deak","year":"2014","journal-title":"Lupus"},{"key":"R12-20230828","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/acr.23584","article-title":"The impact of systemic lupus erythematosus on the clinical phenotype of antiphospholipid antibody positive patients: results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository","volume":"71","author":"Unlu","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R13-20230828","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/01.md.0000172074.53583.ea","article-title":"Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?","volume":"84","author":"Gomez-Puerta","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"R14-20230828","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10067-013-2472-3","article-title":"Distinct antibody profile: a clue to primary antiphospholipid syndrome evolving into systemic lupus erythematosus?","volume":"33","author":"Freire","year":"2014","journal-title":"Clin Rheumatol"},{"key":"R15-20230828","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/ard.56.3.194","article-title":"Thrombocytopenia in the antiphospholipid syndrome","volume":"56","author":"Cuadrado","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"R16-20230828","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1111\/jth.13763","article-title":"Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study","volume":"15","author":"Hisada","year":"2017","journal-title":"J Thromb Haemost"},{"key":"R17-20230828","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.medcli.2016.11.026","article-title":"Thrombocytopenia as a thrombotic risk factor in patients with antiphospholipid antibodies without disease criteria","volume":"148","author":"Demetrio Pablo","year":"2017","journal-title":"Med Clin (Barc)"},{"key":"R18-20230828","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1002\/acr.22388","article-title":"Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort","volume":"66","author":"Sciascia","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R19-20230828","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.semarthrit.2017.12.006","article-title":"Extra-criteria manifestations of antiphospholipid syndrome: risk assessment and management","volume":"48","author":"Radin","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R20-20230828","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11926-014-0494-8","article-title":"The significance and management of thrombocytopenia in antiphospholipid syndrome","volume":"17","author":"Artim-Esen","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"R21-20230828","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1046\/j.1365-2141.1997.3063123.x","article-title":"Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome","volume":"98","author":"Godeau","year":"1997","journal-title":"Br J Haematol"},{"key":"R22-20230828","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1055\/s-0038-1642484","article-title":"Antiglycoprotein Ib\/IX and IIb\/IIIa antibodies in patients with antiphospholipid antibodies","volume":"71","author":"Galli","year":"1994","journal-title":"Thromb Haemost"},{"key":"R23-20230828","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1046\/j.1365-2141.1997.2243038.x","article-title":"Antiplatelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia","volume":"98","author":"Macchi","year":"1997","journal-title":"Br J Haematol"},{"key":"R24-20230828","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1182\/blood.V84.12.4203.bloodjournal84124203","article-title":"Prevalence and clinical-significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura","volume":"84","author":"Stasi","year":"1994","journal-title":"Blood"},{"key":"R25-20230828","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s002770050291","article-title":"Specificities of platelet autoantibodies in patients with lupus anticoagulants in primary antiphospholipid syndrome","volume":"74","author":"Panzer","year":"1997","journal-title":"Ann Hematol"},{"key":"R26-20230828","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1600-0609.1994.tb00195.x","article-title":"Specific antiplatelet autoantibodies in patients with antiphospholipid antibodies and thrombocytopenia","volume":"53","author":"Fabris","year":"1994","journal-title":"Eur J Haematol"},{"key":"R27-20230828","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/10245332.2018.1532649","article-title":"Relevance of antiphospholipid antibody profile in the clinical outcome of ITP: a single-centre study","volume":"24","author":"Frison","year":"2019","journal-title":"Hematology"},{"key":"R28-20230828","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s12185-016-1974-6","article-title":"Thromboembolism in patients with immune thrombocytopenia (ITP): a meta-analysis of observational studies","volume":"103","author":"Langeberg","year":"2016","journal-title":"Int J Hematol"},{"key":"R29-20230828","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/blood.V98.6.1760","article-title":"Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study","volume":"98","author":"Diz-Kucukkaya","year":"2001","journal-title":"Blood"},{"key":"R30-20230828","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.thromres.2018.10.017","article-title":"Prevalence and correlates of thrombosis in adults with immune thrombocytopenia: an NIS study","volume":"172","author":"Machin","year":"2018","journal-title":"Thromb Res"},{"key":"R31-20230828","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"key":"R32-20230828","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"},{"key":"R33-20230828","doi-asserted-by":"crossref","DOI":"10.1007\/s12026-018-9047-y","article-title":"Intravenous immunoglobulins for rheumatic disorders and thromboembolic events-a case series and review of the literature","author":"Lidar","year":"2018","journal-title":"Immunol Res"},{"key":"R34-20230828","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146","author":"Arnold","year":"2007","journal-title":"Ann Intern Med"},{"key":"R35-20230828","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11926-009-0074-5","article-title":"Use of rituximab in the antiphospholipid syndrome","volume":"12","author":"Kumar","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"R36-20230828","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/art.37759","article-title":"A pilot open-label phase II trial of rituximab for noncriteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R37-20230828","article-title":"Long-term effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in primary antiphospholipid syndrome","author":"Sciascia","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"R38-20230828","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/ajh.24234","article-title":"Is ITP a thrombophilic disorder?","volume":"91","author":"Rodeghiero","year":"2016","journal-title":"Am J Hematol"},{"key":"R39-20230828","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1177\/0961203312463621","article-title":"Successful treatment of severe thrombocytopenia with romiplostim in a pregnant patient with systemic lupus erythematosus","volume":"21","author":"Alkaabi","year":"2012","journal-title":"Lupus"},{"key":"R40-20230828","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3109\/09537104.2011.634931","article-title":"Thrombopoietin-receptor agonists in haematological disorders: the Danish experience","volume":"23","author":"Gudbrandsdottir","year":"2012","journal-title":"Platelets"},{"key":"R41-20230828","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.3899\/jrheum.140080","article-title":"Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus","volume":"41","author":"Magnano","year":"2014","journal-title":"J Rheumatol"},{"key":"R42-20230828","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s10067-014-2600-8","article-title":"Successful platelet count recovery in lupus-associated thrombocytopenia with the thrombopoietin agonist eltrombopag","volume":"33","author":"Scheinberg","year":"2014","journal-title":"Clin Rheumatol"},{"key":"R43-20230828","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1177\/0961203314559632","article-title":"Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus","volume":"24","author":"Maroun","year":"2015","journal-title":"Lupus"},{"key":"R44-20230828","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.reuma.2015.04.004","article-title":"Thrombopoietin-receptor agonist as a treatment of thrombocytopenia associated with systemic lupus erythematosus","volume":"12","author":"Moreno Martinez","year":"2016","journal-title":"Reumatol Clin"},{"key":"R45-20230828","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1177\/0961203318770023","article-title":"Safety and efficacy of thrombopoeitin mimetics for refractory immune thrombocytopenia purpura in patients with systemic lupus erythematosus or antiphospholipid syndrome: a case series","volume":"27","author":"Lusa","year":"2018","journal-title":"Lupus"},{"key":"R46-20230828","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1177\/0961203313477900","article-title":"Kidney-limited thrombotic microangiopathy in patients with SLE treated with romiplostim","volume":"22","author":"Tomov","year":"2013","journal-title":"Lupus"},{"key":"R47-20230828","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/j.semarthrit.2015.07.008","article-title":"Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostim, a thrombopoietin receptor agonist","volume":"45","author":"LaMoreaux","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"R48-20230828","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/j.semarthrit.2015.10.007","article-title":"Letter to the editor. Commentary to the article: LaMoreaux B, Barbar-smiley F, Ardoin S, Madhoun H. Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostin, a thrombopoietin receptor agonist. Semin Arthritis Rheum 2015 Jul 29.pii: S0049-0172(15)00196-1. DOI:10.1016\/j.semarthrit.2015.07-008. [Epub ahead of print]","volume":"45","author":"Borrell","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"R49-20230828","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/0961203315608257","article-title":"Eltrombopag in systemic lupus erythematosus with antiphospholipid syndrome: thrombotic events","volume":"25","author":"Boulon","year":"2016","journal-title":"Lupus"},{"key":"R50-20230828","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/bjh.14788","article-title":"Use of eltrombopag for secondary immune thrombocytopenia in clinical practice","volume":"178","author":"Gonzalez-Lopez","year":"2017","journal-title":"Br J Haematol"},{"key":"R51-20230828","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/rheumatology\/key119","article-title":"Risk of thrombosis with antiphospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists","volume":"57","author":"Guitton","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R52-20230828","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ajh.1182","article-title":"Correction of thrombocytopenia with aspirin in the primary antiphospholipid syndrome","volume":"68","author":"Alliot","year":"2001","journal-title":"Am J Hematol"},{"key":"R53-20230828","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1177\/096120339500400613","article-title":"Reversal of thrombocytopenia following oral anticoagulation in two patients with primary antiphospholipid syndrome","volume":"4","author":"Ames","year":"1995","journal-title":"Lupus"},{"key":"R54-20230828","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/rheumatology\/36.10.1095","article-title":"Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases","volume":"36","author":"Blanco","year":"1997","journal-title":"Br J Rheumatol"},{"key":"R55-20230828","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/096120339600500116","article-title":"Correction of severe thrombocytopenia with chloroquine in the primary antiphospholipid syndrome","volume":"5","author":"Suarez","year":"1996","journal-title":"Lupus"},{"key":"R56-20230828","doi-asserted-by":"crossref","first-page":"802","DOI":"10.7326\/0003-4819-122-10-199505150-00020","article-title":"Dapsone in thrombocytopenia of the antiphospholipid antibody syndrome","volume":"122","author":"Lesprit","year":"1995","journal-title":"Ann Intern Med"},{"key":"R57-20230828","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/ard.59.11.920","article-title":"Splenectomy for refractory Evans\u2019 syndrome associated with antiphospholipid antibodies: report of two cases","volume":"59","author":"Font","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"R58-20230828","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0049-0172(98)80024-3","article-title":"Autoimmune thrombocytopenia in primary antiphospholipid syndrome and systemic lupus erythematosus: the response to splenectomy","volume":"28","author":"Hakim","year":"1998","journal-title":"Semin Arthritis Rheum"},{"key":"R59-20230828","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1744-9987.1998.tb00095.x","article-title":"Plasma exchange for thrombocytopenia in antiphospholipid syndrome: a case report","volume":"2","author":"Satomi","year":"1998","journal-title":"Ther Apher"},{"key":"R60-20230828","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"key":"R61-20230828","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99445","article-title":"Neutrophil accumulation and NET release contribute to thrombosis in HIT","volume":"3","author":"Gollomp","year":"2018","journal-title":"JCI Insight"},{"key":"R62-20230828","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/blood-2014-02-554980","article-title":"Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS","volume":"124","author":"Proulle","year":"2014","journal-title":"Blood"},{"key":"R63-20230828","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11684-015-0426-7","article-title":"Antibeta(2) glycoprotein I antibodies in complex with beta(2) glycoprotein I induce platelet activation via two receptors: apolipoprotein E receptor 2 \u2019 and glycoprotein I b alpha","volume":"10","author":"Zhang","year":"2016","journal-title":"Front Med"},{"key":"R64-20230828","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/art.39247","article-title":"Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome","volume":"67","author":"Yalavarthi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R65-20230828","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/jlb.57.3.387","article-title":"Neutrophil activation by anti-beta(2) glycoprotein-i monoclonal-antibodies via Fc-gamma receptor-II","volume":"57","author":"Arvieux","year":"1995","journal-title":"J Leukocyte Biol"},{"key":"R66-20230828","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jaut.2010.06.015","article-title":"A novel mechanism of thrombosis in antiphospholipid antibody syndrome","volume":"35","author":"Vlachoyiannopoulos","year":"2010","journal-title":"J Autoimmun"},{"key":"R67-20230828","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood-2009-03-206367","article-title":"beta 2 Glycoprotein I (beta 2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome","volume":"115","author":"Sikara","year":"2010","journal-title":"Blood"},{"key":"R68-20230828","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93897","article-title":"Activated signature of antiphospholipid syndrome neutrophils reveals potential therapeutic target","volume":"2","author":"Knight","year":"2017","journal-title":"JCI Insight"},{"key":"R69-20230828","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/art.39938","article-title":"In vivo role of neutrophil extracellular traps in antiphospholipid antibody-mediated venous thrombosis","volume":"69","author":"Meng","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R70-20230828","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/0961203306075562","article-title":"High prevalence of antibodies to platelet factor 4 heparin in patients with antiphospholipid antibodies in absence of heparin-induced thrombocytopenia","volume":"16","author":"Martin-Toutain","year":"2007","journal-title":"Lupus"},{"key":"R71-20230828","first-page":"13","article-title":"Is there an association between heparin-induced thrombocytopenia (HIT) and autoimmune disease?","volume":"117","author":"Klinkhammer","year":"2018","journal-title":"WMJ"},{"key":"R72-20230828","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/BOR.0000000000000269","article-title":"Treatment of catastrophic antiphospholipid syndrome","volume":"28","author":"Kazzaz","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"R73-20230828","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.autrev.2014.03.002","article-title":"14th International Congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome","volume":"13","author":"Cervera","year":"2014","journal-title":"Autoimmun Rev"},{"key":"R74-20230828","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/jth.13947","article-title":"Thrombocytopenia in high-risk patients with antiphospholipid syndrome","volume":"16","author":"Pontara","year":"2018","journal-title":"J Thromb Haemost"},{"key":"R75-20230828","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/ard.2003.019000","article-title":"The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women","volume":"64","author":"Le Thi Thuong","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R76-20230828","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/0961203308101958","article-title":"Primary antiphospholipid syndrome with thrombotic thrombocytopenic purpura: a very unusual association","volume":"18","author":"de Carvalho","year":"2009","journal-title":"Lupus"},{"key":"R77-20230828","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/MBC.0000000000000608","article-title":"A rare combination of thrombotic thrombocytopenic purpura and antiphospholipid syndrome","volume":"28","author":"Viner","year":"2017","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R78-20230828","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1002\/art.20551","article-title":"Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome","volume":"50","author":"Amoura","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R79-20230828","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1177\/1076029615625832","article-title":"Plasma ADAMTS13, von Willebrand factor (VWF), and VWF propeptide profiles in patients with connective tissue diseases and antiphospholipid syndrome","volume":"23","author":"Habe","year":"2017","journal-title":"Clin Appl Thromb Hemost"},{"key":"R80-20230828","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1365-2141.2008.07074.x","article-title":"The VWF\/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction","volume":"141","author":"Austin","year":"2008","journal-title":"Br J Haematol"},{"key":"R81-20230828","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/MBC.0000000000000512","article-title":"Thrombotic risk of reduced ADAMTS13 activity in patients with antiphospholipid antibodies","volume":"27","author":"Lee","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R82-20230828","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/rth2.12090","article-title":"Effects of antibeta2GPI antibodies on VWF release from human umbilical vein endothelial cells and ADAMTS13 activity","volume":"2","author":"Ng","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"R83-20230828","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.rdc.2018.06.010","article-title":"Thrombotic microangiopathies with rheumatologic involvement","volume":"44","author":"Babar","year":"2018","journal-title":"Rheum Dis Clin North Am"},{"key":"R84-20230828","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejogrb.2015.03.017","article-title":"Differentiation between severe HELLP syndrome and thrombotic microangiopathy, thrombotic thrombocytopenic purpura and other imitators","volume":"189","author":"Pourrat","year":"2015","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R85-20230828","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s11926-014-0482-z","article-title":"Catastrophic APS in the context of other thrombotic microangiopathies","volume":"17","author":"Rodriguez-Pinto","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"R86-20230828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.05.007","article-title":"The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review","volume":"92","author":"Cervera","year":"2018","journal-title":"J Autoimmun"},{"key":"R87-20230828","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11239-017-1478-0","article-title":"Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study","volume":"43","author":"Mantha","year":"2017","journal-title":"J Thromb Thrombolysis"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201905000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T05:34:10Z","timestamp":1693200850000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201905000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000595","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}